A Double-blind, Placebo-controlled, Randomized, Single Ascending Dose Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ 53718678 in Healthy Japanese Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 13 Jul 2017
At a glance
- Drugs JNJ 53718678 (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Janssen Research & Development
- 24 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 Jun 2015 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 27 Mar 2015 New trial record